Kisspeptin-10 Injections

IHH is caused by mutations in the KISS1/KISS1R gene or insufficient secretion of endogenous Kisspeptin, resulting in GnRH pulse deficiency and low LH/FSH levels, manifested as puberty agenesis, gonadal dysfunction, and infertility. KP-10 injection is the etiological targeted therapy.
Effect: Subcutaneous injection of KP-10 (1-2 μ g/kg, 1-2 times a day) can restore LH pulse secretion, increase male LH pulse frequency by 2 times, and increase testosterone levels from<100ng/dL to 300-600ng/dL; Women resume their menstrual cycle and their estradiol levels normalize.
Clinical advantages: replacing traditional GnRH pulse pumps, convenient administration, and good tolerability; Natural activation of the HPG axis improves sperm production and ovarian function, which is superior to exogenous LH/FSH replacement therapy.

The core pathology of PCOS is disorder of the HPG axis, high LH secretion, polycystic ovary like changes, and ovulation disorders. KP-10 plays a therapeutic role by regulating LH pulses, restoring ovulation, and improving insulin resistance.
Effect: Low dose KP-10 (0.5-1 μ g/kg) can reduce LH levels, improve LH/FSH ratio, and reduce ovarian androgen synthesis; Restore regular ovulation, increase ovulation rate by 40% -60%; Improve insulin sensitivity, reduce serum insulin levels, and alleviate PCOS related metabolic disorders.
Mechanism: Regulating the hypothalamic GnRH pulse rhythm and inhibiting abnormal LH high secretion; Directly acting on ovarian KISSSR, improving follicular development; Regulating pancreatic beta cell function and promoting glucose dependent insulin secretion.

CPP, due to excessive secretion of Kisspeptin in the hypothalamus and premature activation of the HPG axis, leads to early development of secondary sexual characteristics and premature closure of epiphyses in children. Low dose rhythmic injection of KP-10 can inhibit the excessive release of endogenous Kisspeptin and delay the process of precocious puberty.
Effect: Low dose KP-10 (0.2-0.5 μ g/kg, once every other day) can downregulate the expression of KISS1 in the hypothalamus, inhibit excessive secretion of GnRH, reduce LH peak, and delay the development of secondary sexual characteristics; Delaying epiphyseal closure and improving adult height prognosis.
Advantages: Compared to traditional GnRH agonists, it has better reversibility, fewer side effects, and avoids osteoporosis and metabolic abnormalities caused by long-term inhibition of the HPG axis.

Male testosterone deficiency (primary/secondary) is characterized by decreased libido, erectile dysfunction, decreased muscle mass, and infertility. KP-10 injection activates the HPG axis, promotes endogenous testosterone synthesis, and achieves physiological testosterone supplementation.
Effect: Subcutaneous injection of KP-10 (100-200 μ g/time, once daily, 4-6 weeks) can increase LH levels by 3-5 times and testosterone levels from<300ng/dL to 500-800ng/dL; Improving libido and erectile function, increasing sperm concentration and vitality, and increasing natural conception rate.
Application scenario: testosterone replacement therapy (TRT) assisted in restoring HPG axis function; After steroid cycle, the HPG axis restarts, rapidly restoring endogenous testosterone secretion, which is superior to traditional SERMs (clomiphene, tamoxifen).

Traditional ovulation induction can easily lead to ovarian hyperstimulation syndrome (OHSS), asynchronous follicular development, and low egg retrieval rate.Kisspeptin-10 Injections is used as an alternative to GnRH agonists to accurately regulate ovulation timing and improve follicle quality.
Effect: During IVF cycles, dual doses of KP-10 (9.6nmol/kg, with a 12 hour interval) can synchronize follicular development and increase egg retrieval rate by 60%;

Trigger endogenous LH peak, naturally induce ovulation, and avoid OHSS risk caused by HCG injection; Improve egg maturity, increase high-quality embryo rate by 30%, and increase clinical pregnancy rate by 20%.
Mechanism: Simulate physiological LH peaks to promote follicle maturation and ovulation; Regulate local blood flow in the ovaries and improve follicle nutrition supply; Reduce the dosage of ovulation inducing drugs and lower ovarian stress.

KP-10 enhances the clinical pregnancy rate and live birth rate of ART by regulating endometrial receptivity, promoting embryo implantation, and improving pregnancy maintenance.
Effect: Inject KP-10 (1 μ g/kg, once daily) 3-5 days before embryo transfer to upregulate endometrial receptivity markers (LIF, HOXA10), improve endometrial thickness and blood flow; Promote invasion of trophoblast cells and increase embryo implantation rate by 25%; Reduce early miscarriage rate and improve pregnancy outcomes.
Advantages: Compared to traditional progesterone support, it regulates both endocrine and endometrial functions, resulting in a higher success rate of implantation and no progesterone related side effects.

KP-10 treats idiopathic oligozoospermia by activating the HPG axis, promoting sperm production, and improving sperm motility.
Effect: Subcutaneous injection of KP-10 (150 μ g/time, once daily, 8-12 weeks) increases FSH levels by 2-3 times, increases sperm concentration from<15 × 10 ⁶/mL to 30-60 × 10 ⁶/mL, and increases forward motility sperm rate to over 40%; Improve sperm DNA integrity, reduce sperm fragmentation rate, and increase natural conception rate.
Mechanism: FSH promotes the proliferation of seminiferous epithelium in the seminiferous tubules of the testes, enhancing sperm production; Testosterone improves epididymal function, enhances sperm motility and maturity.